Incyte's Jakafi boosts survival in pancreatic cancer patients; Novartis taps Dublin site for 100 new jobs;

@FiercePharma: Top story yesterday: Analyst urges Merck to chop costs, preferably $1B-plus. Article | Follow @FiercePharma

@EricPFierce: Alexion recalls some Soliris in EC "due to the presence of visible particles in a limited number of vials." More from FiercePharmaManufacturing | Follow @EricPFierce

@CarlyHFierce: Shire enlists help fighting unwanted takeover. Another co. seeking access to Ireland's tax regime? Popular yesterday from FiercePharma | Follow @CarlyHFierce

> The myelofibrosis drug Jakafi, marketed by Incyte ($INCY) and Novartis ($NVS), improved survival in pancreatic cancer patients when used with the chemo drug capecitabine, compared with capecitabine alone. Report

> Novartis found its site in Dublin for a new regional business services center, now temporarily housed elsewhere in the region; the company says it's still on track to hire 100 people by year's end. Report

> Despite turmoil in some of its primary markets, Jordan-based Hikma Pharmaceuticals once again hiked its sales forecast after a 20% revenue increase in the first half of the year. Report

> India's Zydus Cadila won the FDA nod to market its version of the Takeda acid reflux remedy Prevacid in the U.S. Report

> Par Pharmaceutical's version of Wellbutrin XL cleared FDA scrutiny after the agency asked all generics makers selling the pills to study them again for bioequivalence. Report

> Novartis' generics unit Sandoz relaunched the website promoting its biosimilars business. Report

Medical Device News

@FierceMedDev: Popular this week: Inventor launches crowdfunding hub for medical devices. Article | Follow @FierceMedDev

@DamianFierce: Finally, some good news for Navidea: Medicare expansion and a Siemens partnership. Report | Follow @DamianFierce

@MarkHFierce: In 2012, medical device employment at the top companies mostly grew, due to M&A and organic growth. ICYM the feature | Follow @MarkHFierce

> Boston Scientific wins FDA nods for electrophysiology tech. More

> Medtronic's Ishrak outlines health services expansion plans. Article

> Quest dumps $1B into repurchase plan as sales ail. Story

> Acutus Medical closes $28M round for arrhythmia mapping device. Item

Biotech News

@FierceBiotech: Popular yesterday: Novartis wins a record breakthrough therapy designation for orphan drug. Article | Follow @FierceBiotech

@JohnCFierce: Just came across my story on first IPO of '13 - $STML, priced at $10, now $34.55. Hopeful signs, indeed. Article | Follow @JohnCFierce

@EmilyMFierce: This week's issue of FierceBiotechResearch. Report | Follow @EmilyMFierce

> Basilea shares dented after FDA digs in on antibiotic PhIII rule. Story

> Trial co-op persuades pharmas to stop sabotaging head-to-head drug studies. More

> Incyte shares surge on positive pancreatic cancer trial data for Jakafi. News

Biomarkers News

> Blood samples may aid suicide risk prediction. Story

> Possible psychosis biomarker found in brain "folding." Story

> Potential Alzheimer's biomarker targeted in brain fluid. More

> Lung cancer gene variants could help boost survival odds. Article

> Biomarker gauges graft-versus-host disease risk for stem cell transplant patients. Item

Drug Delivery News

@MichaelGFierce: Time-release delivery of vision-loss drug demands fewer injections. More | Follow @MichaelGFierce

> Study: Insulin pumps improve glycemic control in children with diabetes. Story

> Bind launches second PhII trial for prostate cancer nanomed. More

> Alnylam wins two orphan designations for hemophilia RNAi drug. Report

> Platinum-based radiotherapy method zaps cancer with nanomeds. Article

And Finally... Exercise can be as good as a pill for insomniacs, but only if they stick with the program long-term. Report

Suggested Articles

Novartis said it plans to use the complete response rate data for a U.S. filing in follicular lymphoma in 2021.

Sen. Elizabeth Warren asked the SEC to probe Kodak trades made before the Trump administration unveiled their drug supply deal—and $765M in funding.

Amarin's wild 2020 ride continues with plans to launch its cardiovascular med Vascepa in Europe without a bigger marketing partner.